Cancer Research UK and Medidata have revealed that the Medidata Clinical Cloud has been chosen to support the charity’s drug discovery research.
Cancer Research UK’s Centre for Drug Development (CDD) will leverage Medidata’s cloud-based technology for electronic data capture and management in order to conduct faster and safer clinical trials at institutes, universities and hospitals across the UK.
Dr Nigel Blackburn, director of Cancer Research UK’s CDD, commented: “Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress across all our trials.
“Having immediate access to high quality data will ultimately help us shorten trial delivery times, reduce costs and maximise the output of studies so that we can accelerate progress and bring new treatments to cancer patients sooner.”
Medidata’s system will make clinical data from the CDD’s future trials easily accessible to researchers in real time, streamlining the process of launching and running cancer trials.
The centralised system will improve data quality, allow clinicians to easily monitor patients’ safety and enable more educated decision-making across all trials.
Glen de Vries, Medidata’s president, said: “Cancer Research UK is recognised internationally for its vital leadership in helping to increase cancer survival rates and Medidata is thrilled to be part of its journey.”
“We share Cancer Research UK’s quest for improved patient outcomes and are committed to providing technology that helps fuel innovation to uncover new approaches to cancer diagnosis, treatment and prevention.”
The announcement comes just a week after the charity announced a partnership with the engineering and physical sciences research council (EPSRC) to co-fund multidisciplinary research projects.
